Here are the 10-K annual reports from Verastem, Inc. (VSTM) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow VSTM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VSTM filings page.
Verastem, Inc. outlines a pivotal year transforming into a commercial-stage oncology company focused on RAS/MAPK pathway-driven cancers. The company markets AVMAPKI FAKZYNJA CO-PACK in the U.S., the first FDA-approved therapy specifically for KRAS‑mutated recurrent low‑grade serous ovarian cancer.
AVMAPKI FAKZYNJA CO-PACK received accelerated approval in May 2025, was commercially available within a week, and generated $30.9 million in net product revenue over its first seven months. A global Phase 3 confirmatory trial (RAMP 301) fully enrolled ahead of schedule and is intended to support full approval and a broader LGSOC label.
Beyond LGSOC, Verastem is advancing avutometinib plus defactinib in first-line pancreatic cancer (RAMP 205) and developing VS-7375, a selective oral KRAS G12D ON/OFF inhibitor licensed from GenFleet. VS-7375 is in U.S. Phase 1/2 trials and has FDA Fast Track designations in KRAS G12D-mutated pancreatic cancer.